Hepatic PPAR is not essential for the rapid development of steatosis after loss of hepatic gh signaling, in adult male mice

Endocrinology

Volumn 157, Issue 5, 2016, Pages 1728-1735

  Kineman, Rhonda D ^a,b   Majumdar, Neena ^a,b   Subbaiah, Papasani V ^a,b   Cordoba Chacon, Jose ^a,b  

^a JESSE BROWN VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLGLYCEROL PALMITOYLTRANSFERASE; CD36 ANTIGEN; FATTY ACID; GROWTH HORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL; GROWTH HORMONE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DE NOVO LIPOGENESIS; ESTERIFICATION; FATTY LIVER; GENE EXPRESSION; LIPID LIVER LEVEL; LIPOGENESIS; LIVER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; LIVER; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; FATTY LIVER; GROWTH HORMONE; HEPATOCYTES; LIPOGENESIS; LIVER; MALE; MICE; MICE, KNOCKOUT; PPAR GAMMA; RECEPTORS, SOMATOTROPIN; SIGNAL TRANSDUCTION;

EID: 84969779599     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-2077     Document Type: Article

References (62)

1. Rui L. Energy metabolism in the liver. Compr Physiol. 2014;4(1): 177-197.
2. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146(3): 726-735.
3. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343-1351.
4. Donnelly KL, Margosian MR, Sheth SS, Lusis AJ, Parks EJ. Increased lipogenesis and fatty acid reesterification contribute to hepatic triacylglycerol stores in hyperlipidemic Txnip-/ mice. J Nutr. 2004;134(6):1475-1480.
5. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011; 9(6):524-530. e521; quiz e60.
6. Zezos P, Renner EL. Liver transplantation and non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20(42):15532-15538.
7. Cordoba-Chacon J, Majumdar N, List EO, et al. Growth hormone inhibits hepatic de novo lipogenesis in adult mice. Diabetes. 2015; 64(9):3093-3103.
8. Arturi F, Succurro E, Procopio C, et al. Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab. 2011;96(10):E1640-E1644.
9. Fusco A, Miele L, D'Uonnolo A, et al. Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels. Clin Endocrinol (Oxf). 2012;77(4):531-536.
10. Cianfarani S, Inzaghi E, Alisi A, Germani D, Puglianiello A, Nobili V. Insulin-like growth factor-I and-II levels are associated with the progression of nonalcoholic fatty liver disease in obese children. J Pediatr. 2014;165(1):92-98.
11. García-Galiano D, Sánchez-Garrido MA, Espejo I, et al. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and nonalcoholic steatohepatitis in morbidly obese patients. Obes Surg. 2007;17(4):493-503.
12. Hribal ML, Procopio T, Petta S, et al. Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2013;98(2):E304-E308.
13. Ichikawa T, Nakao K, Hamasaki K, et al. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binDing protein 3 in development of non-alcoholic fatty liver disease. Hepatol Int. 2007;1(2):287-294.
14. Runchey SS, Boyko EJ, Ioannou GN, Utzschneider KM. Relationship between serum circulating insulin-like growth factor-1 and liver fat in the United States. J Gastroenterol Hepatol. 2014;29(3):589-596.
15. Sesti G, Hribal ML, Procopio T, et al. Low circulating insulin-like growth factor-1 levels are associated with high serum uric acid in nondiabetic adult subjects. Nutr Metab Cardiovasc Dis. 2014; 24(12):1365-1372.
16. Sirbu A, Gologan S, Arbanas T, et al. Adiponectin, body mass index and hepatic steatosis are independently associated with IGF-I status in obese non-diabetic women. Growth Horm IGF Res. 2013;23(1-2):2-7.
17. Sumida Y, Yonei Y, Tanaka S, et al. Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease. Hepatol Res. 2015;45(7):771-781.
18. Hazlehurst JM, Tomlinson JW. Non-alcoholic fatty liver disease in common endocrine disorders. Eur J Endocrinol. 2013;169(2):R27-R37.
19. Xu L, Xu C, Yu C, et al. Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study. PLoS One. 2012;7(8):e44136.
20. Madsen M, Krusenstjerna-Hafstrøm T, Møller L, et al. Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and aGHreceptor antagonist: a randomized clinical trial. J Clin Endocrinol Metab. 2012;97(4):1227-1235.
21. Takahashi Y, Iida K, Takahashi K, et al. Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology. 2007;132(3):938-943.
22. Nishizawa H, Iguchi G, Murawaki A, et al. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact ofGHreplacement therapy. Eur J Endocrinol. 2012;167(1): 67-74.
23. Gardner CJ, Irwin AJ, Daousi C, et al. Hepatic steatosis, GH deficiency and the effects of GH replacement: a Liverpool magnetic resonance spectroscopy study. Eur J Endocrinol. 2012;166(6):993-1002.
24. Owen C, Lees EK, Mody N, Delibegovic M. Regulation of growth hormone induced JAK2 and mTOR signalling by hepatic protein tyrosine phosphatase 1B. Diabetes Metab. 2014;41(1):95:95-101.
25. Bielohuby M, Sawitzky M, Stoehr BJ, et al. Lack of dietary carbohydrates induces hepatic growth hormone (GH) resistance in rats. Endocrinology. 2011;152(5):1948-1960.
26. Qin Y, Tian YP. Preventive effects of chronic exogenous growth hormone levels on diet-induced hepatic steatosis in rats. Lipids Health Dis. 2010;9:78.
27. Yang T, Householder LA, Lubbers ER, et al. Growth hormone receptor antagonist transgenic mice are protected from hyperinsulinemia and glucose intolerance despite obesity when placed on a HF diet. Endocrinology. 2014;155(2):555-564.
28. List EO, Palmer AJ, Berryman DE, Bower B, Kelder B, Kopchick JJ. Growth hormone improves body composition, fasting blood glucose, glucose tolerance and liver triacylglycerol in a mouse model of diet-induced obesity and type 2 diabetes. Diabetologia. 2009;52(8): 1647-1655.
29. Tateno C, Kataoka M, Utoh R, et al. Growth hormone-dependent pathogenesis of human hepatic steatosis in a novel mouse model bearing a human hepatocyte-repopulated liver. Endocrinology. 2011;152(4):1479-1491.
30. Pettinelli P, Videla LA. Up-regulation of PPAR-mRNAexpression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. J Clin Endocrinol Metab. 2011; 96(5):1424-1430.
31. Inoue M, Ohtake T, Motomura W, et al. Increased expression of PPAR in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun. 2005;336(1):215-222.
32. Matsusue K, Haluzik M, Lambert G, et al. Liver-specific disruption ofPPAR in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest. 2003;111(5):737-747.
33. Morán-Salvador E, López-Parra M, García-Alonso V, et al. Role for PPAR in obesity-induced hepatic steatosis as determined by hepatocyte-and macrophage-specific conditional knockouts. FASEB J. 2011;25(8):2538-2550.
34. Gavrilova O, Haluzik M, Matsusue K, et al. Liver peroxisome proliferator-activated receptor contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem. 2003;278(36):34268-34276.
35. Yamazaki T, Shiraishi S, Kishimoto K, Miura S, Ezaki O. An increase in liver PPAR-2 is an initial event to induce fatty liver in response to a diet high in butter:PPAR-2 knockdown improves fatty liver induced by high-saturated fat. J Nutr Biochem. 2011;22(6): 543-553.
36. Vidal-Puig A, Jimenez-Liñan M, Lowell BB, et al. Regulation of PPAR gene expression by nutrition and obesity in rodents. J Clin Invest. 1996;97(11):2553-2561.
37. Barclay JL, Nelson CN, Ishikawa M, et al. GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. Endocrinology. 2011;152(1):181-192.
38. Sos BC, Harris C, Nordstrom SM, et al. Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2. J Clin Invest. 2011;121(4):1412-1423.
39. Fan Y, Menon RK, Cohen P, et al. Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism. J Biol Chem. 2009;284(30): 19937-19944.
40. Matsusue K, Aibara D, Hayafuchi R, et al. Hepatic PPAR and LXR independently regulate lipid accumulation in the livers of genetically obese mice. FEBS Lett. 2014;588(14):2277-2281.
41. Schadinger SE, Bucher NL, Schreiber BM, Farmer SR. PPAR-2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab. 2005;288(6):E1195-E1205.
42. Zhang YL, Hernandez-Ono A, Siri P, et al. Aberrant hepatic expression of PPAR-2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. J Biol Chem. 2006;281(49):37603-37615.
43. Lee YJ, Ko EH, Kim JE, et al. Nuclear receptor PPAR-regulated monoacylglycerol O-acyltransferase 1 (MGAT1) expression is responsible for the lipid accumulation in diet-induced hepatic steatosis. Proc Natl Acad Sci USA. 2012;109(34):13656-13661.
44. List EO, Berryman DE, Funk K, et al. The role of GH in adipose tissue: lessons from adipose-specific GH receptor gene-disrupted mice. Mol Endocrinol. 2013;27(3):524-535.
45. Cordoba-Chacon J, Gahete MD, McGuinness OP, Kineman RD. Differential impact of selective GH deficiency and endogenous GH excess on insulin-mediated actions in muscle and liver of male mice. Am J Physiol Endocrinol Metab. 2014;307(10):E928-E934.
46. Vandesompele J,DePreter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7):RESEARCH0034.
47. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37(8):911-917.
48. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPAR-. Annu Rev Biochem. 2008;77:289-312.
49. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPAR promotes monocyte/macrophage differentiation and uptake of oxiDized LDL. Cell. 1998;93(2):241-252.
50. Kim TH, Kim H, Park JM, et al. Interrelationship between liver X receptor , sterol regulatory element-binDing protein-1c, peroxisome proliferator-activated receptor , and small heterodimer partner in the transcriptional regulation of glucokinase gene expression in liver. J Biol Chem. 2009;284(22):15071-15083.
51. Chong MF, Hodson L, Bickerton AS, et al. Parallel activation of de novo lipogenesis and stearoyl-CoA desaturase activity after 3 d of high-carbohydrate feeding. Am J Clin Nutr. 2008;87(4):817-823.
52. Silbernagel G, Kovarova M, Cegan A, et al. High hepatic SCD1 activity is associated with low liver fat content in healthy subjects under a lipogenic diet. J Clin Endocrinol Metab. 2012;97(12): E2288-E2292.
53. Peter A, Cegan A, Wagner S, et al. Hepatic lipid composition and stearoyl-coenzyme A desaturase 1 mRNA expression can be estimated from plasma VLDL fatty acid ratios. Clin Chem. 2009; 55(12):2113-2120.
54. Lee JJ, Lambert JE, Hovhannisyan Y, et al. Palmitoleic acid is ele-vated in fatty liver disease and reflects hepatic lipogenesis. AmJ Clin Nutr. 2015;101(1):34-43.
55. Zhou J, Febbraio M, Wada T, et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPAR in promoting steatosis. Gastroenterology. 2008;134(2):556-567.
56. Cui Y, Hosui A, Sun R, et al. Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration. Hepatology. 2007;46(2):504-513.
57. List EO, Berryman DE, Funk K, et al. Liver-specific GH receptor gene-disrupted (LiGHRKO) mice have decreased endocrine IGF-I, increased local IGF-I, and altered body size, body composition, and adipokine profiles. Endocrinology. 2014;155(5):1793-1805.
58. Mueller KM, Kornfeld JW, Friedbichler K, et al. Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology. 2011;54(4):1398-1409.
59. Liu Z, Cronstein B, Liu H, et al. IGF-1-independent actions of liver growth hormone receptor in male mice. The Endocrine Society's 98th Annual Meeting, Expo Boston, Boston, MA, 2016. OR40-2.
60. Wakao H, Wakao R, Oda A, Fujita H. Constitutively active Stat5A and Stat5B promote adipogenesis. Environ Health Prev Med. 2011; 16(4):247-252.
61. Grygiel-Gorniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications-a review. Nutr J. 2014;13:17.
62. Chen L, Wang C, Huang S, et al. Effects of individual and multiple FAs (palmitate, oleate and docosahaexenoic acid) on cell viability and lipid metabolism in LO2 human liver cells. Mol Med Rep. 2014; 10(6):3254-3260.